SG11201501510SA - Combinations of sglt2 inhibitors and antihypertensive drugs - Google Patents

Combinations of sglt2 inhibitors and antihypertensive drugs

Info

Publication number
SG11201501510SA
SG11201501510SA SG11201501510SA SG11201501510SA SG11201501510SA SG 11201501510S A SG11201501510S A SG 11201501510SA SG 11201501510S A SG11201501510S A SG 11201501510SA SG 11201501510S A SG11201501510S A SG 11201501510SA SG 11201501510S A SG11201501510S A SG 11201501510SA
Authority
SG
Singapore
Prior art keywords
combinations
antihypertensive drugs
sglt2 inhibitors
sglt2
inhibitors
Prior art date
Application number
SG11201501510SA
Other languages
English (en)
Inventor
Naoki Kojima
J Richard Roman
Noriyuki Miyata
Teisuke Takahashi
Hideki Tomoike
Takuya Takeda
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of SG11201501510SA publication Critical patent/SG11201501510SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201501510SA 2012-08-30 2013-08-30 Combinations of sglt2 inhibitors and antihypertensive drugs SG11201501510SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261695016P 2012-08-30 2012-08-30
PCT/JP2013/073300 WO2014034842A1 (ja) 2012-08-30 2013-08-30 Ｓｇｌｔ２阻害薬と抗高血圧薬との組み合わせ

Publications (1)

Publication Number Publication Date
SG11201501510SA true SG11201501510SA (en) 2015-04-29

Family

ID=50183647

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501510SA SG11201501510SA (en) 2012-08-30 2013-08-30 Combinations of sglt2 inhibitors and antihypertensive drugs

Country Status (17)

Country Link
US (1) US9320727B2 (enrdf_load_html_response)
EP (1) EP2891499A4 (enrdf_load_html_response)
JP (2) JP6198013B2 (enrdf_load_html_response)
KR (1) KR20150046125A (enrdf_load_html_response)
CN (1) CN104780942A (enrdf_load_html_response)
AU (1) AU2013309904A1 (enrdf_load_html_response)
BR (1) BR112015004012A2 (enrdf_load_html_response)
CA (1) CA2883118A1 (enrdf_load_html_response)
HK (1) HK1208621A1 (enrdf_load_html_response)
IN (1) IN2015DN01975A (enrdf_load_html_response)
MX (1) MX2015002572A (enrdf_load_html_response)
PH (1) PH12015500434B1 (enrdf_load_html_response)
RU (1) RU2015110979A (enrdf_load_html_response)
SG (1) SG11201501510SA (enrdf_load_html_response)
TW (1) TW201414472A (enrdf_load_html_response)
WO (1) WO2014034842A1 (enrdf_load_html_response)
ZA (1) ZA201502009B (enrdf_load_html_response)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101943382B1 (ko) * 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
CN109806397A (zh) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 Sglt2抑制剂与arb联合在制备治疗高血压等疾病的药物中的用途
KR102131359B1 (ko) * 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물
JP7659783B2 (ja) 2019-09-13 2025-04-10 国立大学法人富山大学 急性心不全における体液貯留改善薬
CN115916197A (zh) * 2020-04-22 2023-04-04 拜耳公司 用于治疗和/或预防心血管和/或肾脏疾病的非奈利酮和sglt2抑制剂的组合
KR20230057388A (ko) * 2020-08-17 2023-04-28 티엔진 크레아트론 바이오테크놀로지 컴파니 리미티드 Sglt-2 억제제와 안지오텐신 수용체 길항제의 조성물 및 이의 용도
JP7168133B1 (ja) * 2021-02-19 2022-11-09 大正製薬株式会社 経口フィルム製剤
EP4424309A4 (en) * 2021-10-27 2025-02-26 Meditake Co., Ltd. COMPOSITION WITH ANGIOTENSIN RECEPTOR BLOCKER AND SGLT2 INHIBITOR
CN120417911A (zh) * 2022-12-20 2025-08-01 斯法姆公司 包含钠-葡萄糖协同转运蛋白2抑制剂和血管紧张素ⅱ受体阻滞剂的用于预防或治疗心血管疾病的药物组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
DE102004048388A1 (de) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
JP5194588B2 (ja) * 2006-07-06 2013-05-08 大正製薬株式会社 １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤
TW200904405A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
CN101754972A (zh) * 2007-05-18 2010-06-23 百时美施贵宝公司 Sglt2抑制剂的晶体结构及其制备方法
WO2010048358A2 (en) * 2008-10-22 2010-04-29 Auspex Pharmaceutical, Inc. Ethoxyphenylmethyl inhibitors of sglt2
AU2010237748B2 (en) * 2009-04-16 2014-10-30 Taisho Pharmaceutical Co., Ltd. Pharmaceutical compositions
JP2012528170A (ja) 2009-05-27 2012-11-12 ブリストル−マイヤーズ スクイブ カンパニー 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法

Also Published As

Publication number Publication date
EP2891499A1 (en) 2015-07-08
ZA201502009B (en) 2016-07-27
MX2015002572A (es) 2015-06-05
IN2015DN01975A (enrdf_load_html_response) 2015-08-14
WO2014034842A1 (ja) 2014-03-06
EP2891499A4 (en) 2016-02-24
JP2017186353A (ja) 2017-10-12
HK1208621A1 (en) 2016-03-11
JP6198013B2 (ja) 2017-09-20
KR20150046125A (ko) 2015-04-29
CN104780942A (zh) 2015-07-15
BR112015004012A2 (pt) 2017-07-04
RU2015110979A (ru) 2016-10-20
US9320727B2 (en) 2016-04-26
PH12015500434B1 (en) 2022-04-22
US20150320721A1 (en) 2015-11-12
JPWO2014034842A1 (ja) 2016-08-08
TW201414472A (zh) 2014-04-16
CA2883118A1 (en) 2014-03-06
JP6358515B2 (ja) 2018-07-18
PH12015500434A1 (en) 2015-04-20
AU2013309904A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
IL237849A0 (en) ret suppressors and their uses
SG11201406948PA (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
IL252566A0 (en) Pharmacy preparations and methods
EP2776837A4 (en) COMBINATION OF KINASEINHIBITORS AND THEIR USE
IL225862A0 (en) Inhibitors for Nampt and Rock
ZA201408720B (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
ZA201502009B (en) Combinations of sglt2 inhibitors and antihypertensive drugs
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
EP2928384A4 (en) ANCHORS CAPTURED BY THE FABRIC AND METHOD OF USE
ZA201405535B (en) Inhibitors of iap
ZA201409508B (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
GB201208315D0 (en) Pharmaceutical methods and compositions
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
ZA201405644B (en) Weatherised minerals and methods of making and using same
EP2870133A4 (en) TETRAHYDRO ISOHUMULOD DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF
GB201203988D0 (en) Selective glycosidase inhibitors and uses thereof
GB201203987D0 (en) Selective glycosidase inhibitors and uses thereof
GB201203614D0 (en) Selective glycosidase inhibitors and uses thereof
GB201203617D0 (en) Selective glycosidase inhibitors and uses thereof
GB201203621D0 (en) Selective glycosidase inhibitors and uses thereof
GB201204455D0 (en) Barrier means and method of use thereof